SCHEMBL2026078

SCHEMBL2026078

NCCNCCN[C@@H](COCc1ccccc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.50
PPARA Q07869 2/20 0.49
SLC1A1 P43005 3/20 0.46
PPARG P37231 1/20 0.45
MME P08473 1/20 0.45
CTSS P25774 1/20 0.41
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
GGT1 P19440 1/20 0.40
MMP9 P14780 1/20 0.40
MMP14 P50281 1/20 0.40
ITGB3 P05106 4/20 0.40
ITGA2B P08514 4/20 0.40
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2026077 1.00 FOLH1 (0.50) FOLH1PPARASLC1A1PPARGMME
SCHEMBL6446640 0.99 FOLH1 (0.49) FOLH1PPARASLC1A1PPARGMME
SCHEMBL6446635 0.99 FOLH1 (0.49) FOLH1PPARASLC1A1PPARGMME
SCHEMBL9450975 0.92 FOLH1 (0.54) FOLH1PPARASLC1A1PPARGMME
SCHEMBL5347315 0.92 FOLH1 (0.54) FOLH1PPARASLC1A1PPARGMME
SCHEMBL7588488 0.89 FOLH1 (0.59) FOLH1PPARASLC1A1PPARGMME
SCHEMBL6446637 0.89 FOLH1 (0.42) FOLH1PPARASLC1A1PPARGMME
SCHEMBL9115844 0.85 MMP9 (0.43) FOLH1PPARASLC1A1PPARGMME
SCHEMBL9450999 0.84 FOLH1 (0.50) FOLH1PPARASLC1A1PPARGMME
SCHEMBL27740201 0.81 SLC1A1 (0.48) FOLH1PPARASLC1A1SLC1A3SLC1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948590-B1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS BRACCO IMAGING SPA (IT) 2010-08-18 EP claimed
US-20090306424-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS BRACCO IMAGING S.P.A. (IT) 2009-12-10 US claimed
US-7592482-B2 Process for the preparation of contrast agents BRACCO IMAGING S.P.A. (IT) 2009-09-22 US claimed
US-20090118537-A1 Process for the Preparation of Contrast Agents BRACCO IMAGING S.P.A. (IT) 2009-05-07 US claimed
EP-1948590-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS Bracco Imaging S.p.A. (IT) 2008-07-30 EP claimed
WO-2007031390-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS BRACCO IMAGING S.P.A. (IT) 2007-03-22 WO claimed
EP-1762563-A1 Process for the preparation of contrast agents BRACCO IMAGING S.p.A. (IT) 2007-03-14 EP claimed
US-6162947-A Process for the preparation of 4-carboxy-5, 8,11-tris (carboxymethyl)-phenyl-2-oxa-5, 8 11-triazatridecan DIBRA S.P.A. (IT) 2000-12-19 US claimed
US-10106489-B2 Process for the purification of polyaminocarboxylates BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2018-10-23 US disclosed
EP-2782900-B1 PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES BIOPHORE INDIA PHARMACEUTICALS PVT LTD (IN) 2018-01-10 EP disclosed
US-9795695-B2 Process for the preparation of gadobenate dimeglumine complex in a solid form BRACCO IMAGING S.P.A. (IT) 2017-10-24 US disclosed
CN-106986784-A For the method for the Gadobenate Dimeglumine complex compound for preparing solid form 伯拉考成像股份公司 2017-07-28 CN disclosed
US-20160228583-A1 Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form BRACCO IMAGING S.P.A. (IT) 2016-08-11 US disclosed
US-20140323719-A1 PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) 2014-10-30 US disclosed
EP-1762563-A1 Process for the preparation of contrast agents BRACCO IMAGING S.p.A. (IT) 2007-03-14 EP disclosed
CN-1699325-A A process for the preparation of 2-chloro-3-(phenylmethoxy)propionic acid potassium salt BRACCO IMAGING SPA (IT) 2005-11-23 CN disclosed
EP-1095009-B1 A PROCESS FOR THE PREPARATION OF 4-CARBOXY- 5,8,11- TRIS(CARBOXYMETHYL)- 1-PHENYL- 2-OXA- 5,8,11- TRIAZATRIDECAN- 13-OIC ACID BRACCO IMAGING SPA (IT) 2005-06-15 EP disclosed
EP-1095009-A2 A PROCESS FOR THE PREPARATION OF 4-CARBOXY- 5,8,11- TRIS(CARBOXYMETHYL)- 1-PHENYL- 2-OXA- 5,8,11- TRIAZATRIDECAN- 13-OIC ACID Bracco Imaging S.p.A. (IT) 2001-05-02 EP disclosed
US-6162947-A Process for the preparation of 4-carboxy-5, 8,11-tris (carboxymethyl)-phenyl-2-oxa-5, 8 11-triazatridecan DIBRA S.P.A. (IT) 2000-12-19 US disclosed
WO-2000002847-A2 A PROCESS FOR THE PREPARATION OF 4-CARBOXY- 5,8,11- TRIS(CARBOXYMETHYL)- 1-PHENYL- 2-OXA- 5,8,11- TRIAZATRIDECAN- 13-OIC ACID BRACCO S.P.A. (IT) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106489-B2 Process for the purification of polyaminocarboxylates SSTR3, TAC3, PDE3A FOLH1 396/4885PPARA 3142/4885SLC1A1 341/4885
US-20160228583-A1 Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form GCG, SLC6A1, SLC6A11 FOLH1 1498/4885PPARA 728/4885SLC1A1 1933/4885
US-20090306424-A1 PROCESS FOR THE PREPARATION OF CONTRAST AGENTS MGMT, CA14, CA4 FOLH1 298/4885PPARA 4724/4885SLC1A1 2414/4885
US-20140323719-A1 PROCESS FOR THE PURIFICATION OF POLYAMINOCARBOXYLATES SSTR3, TAC3, PDE3A FOLH1 396/4885PPARA 3142/4885SLC1A1 341/4885
US-20090118537-A1 Process for the Preparation of Contrast Agents MGMT, CA14, CA4 FOLH1 298/4885PPARA 4724/4885SLC1A1 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.